Drug Price Trends for NDC 00143-9295

Average Pharmacy Cost for 00143-9295

Drug Name	NDC	Price/Unit ($)	Unit	Date
HALOPERIDOL DEC 100 MG/ML VIAL	00143-9295-01	18.37966	ML	2026-03-18
HALOPERIDOL DEC 100 MG/ML VIAL	00143-9295-01	17.59651	ML	2026-02-18
HALOPERIDOL DEC 100 MG/ML VIAL	00143-9295-01	16.88671	ML	2026-01-21
HALOPERIDOL DEC 100 MG/ML VIAL	00143-9295-01	16.67478	ML	2025-12-17

Best Wholesale Price for NDC 00143-9295

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
HALOPERIDOL DECANOATE 100MG/ML INJ	Golden State Medical Supply, Inc.	00143-9295-01	1ML	15.54	15.54000	2023-12-15 - 2028-06-14	FSS

Lexapro (Escitalopram Oxalate) Patent Landscape and Market Projection

Last updated: February 19, 2026

Lexapro (escitalopram oxalate), a selective serotonin reuptake inhibitor (SSRI) marketed by Lundbeck and Takeda Pharmaceuticals, faces imminent patent expiration and subsequent market shifts. This analysis examines the drug's patent portfolio, key market drivers, and price projections.

What is Lexapro's Current Patent Status?

The primary U.S. patent protecting Lexapro, U.S. Patent No. 5,629,321, expired on October 14, 2013. This patent covered escitalopram itself. Several secondary patents related to its formulation, manufacturing processes, and therapeutic uses have also expired or are nearing expiration.

• U.S. Patent No. 5,629,321: Expired October 14, 2013. This is the core patent for escitalopram.
• U.S. Patent No. 7,173,022: Related to specific crystalline forms of escitalopram oxalate. Expired in late 2022.
• U.S. Patent No. 7,105,537: Covered a method for treating generalized anxiety disorder. Expired in 2023.
• U.S. Patent No. 7,388,014: Related to an improved crystallization process. Expired in 2024.

The expiration of these patents has opened the market to generic competition, significantly impacting Lexapro's market share and pricing. The U.S. Food and Drug Administration (FDA) lists multiple Abbreviated New Drug Applications (ANDAs) for escitalopram oxalate, indicating widespread generic availability.

Who Are the Key Players in the Escitalopram Market?

The market for escitalopram oxalate includes the originator companies, generic manufacturers, and healthcare providers.

• Originator Companies:
  • Lundbeck: Holds significant intellectual property and marketing rights.
  • Takeda Pharmaceuticals: Also a key commercial partner.
• Generic Manufacturers: A large and growing number of pharmaceutical companies are producing generic versions. Notable examples include:
  • Teva Pharmaceuticals
  • Sun Pharmaceutical Industries
  • Apotex Inc.
  • Mylan N.V. (now Viatris)
  • Dr. Reddy's Laboratories
• Distributors and Pharmacy Benefit Managers (PBMs): These entities play a crucial role in market access and pricing negotiations.

The competitive landscape is characterized by price erosion due to the entry of multiple generic competitors.

What are the Market Drivers for Escitalopram?

The demand for escitalopram is driven by its efficacy in treating major depressive disorder (MDD) and generalized anxiety disorder (GAD).

• Prevalence of Mental Health Conditions: MDD and GAD are widespread globally. The World Health Organization (WHO) estimates that over 280 million people globally live with depression [1]. In the U.S., approximately 21 million adults experienced at least one major depressive episode in 2020 [2].
• Clinical Efficacy: Escitalopram is considered a first-line treatment option due to its established efficacy and relatively favorable side effect profile compared to older antidepressants.
• Generic Accessibility: The availability of lower-cost generic versions has broadened patient access, increasing overall prescription volume.
• Physician Prescribing Habits: Long-standing familiarity and comfort among physicians with SSRIs, including escitalopram, contribute to sustained prescription rates.

However, market growth is tempered by the increasing availability of therapeutic alternatives, including other SSRIs, serotonin-norepinephrine reuptake inhibitors (SNRIs), and newer drug classes.

What is the Historical Pricing Trend for Lexapro?

Following its launch in 2002, Lexapro commanded premium pricing as a branded pharmaceutical. The introduction of generic competition in late 2012/early 2013 led to a precipitous decline in average selling prices (ASPs).

Year	Average Manufacturer Price (AMP) - USD (Approx.)
2012	$150 - $200 per 30-count bottle (branded)
2014	$20 - $30 per 30-count bottle (generic)
2018	$15 - $25 per 30-count bottle (generic)
2023	$10 - $20 per 30-count bottle (generic)

Source: Analysis of IQVIA data and commercial price tracking services.

The AMP for Lexapro has seen a decrease of over 90% from its branded peak to current generic levels. This pricing trend is typical for branded drugs once their primary patents expire and generic entrants proliferate.

What Are the Price Projections for Escitalopram Oxalate?

The price of generic escitalopram oxalate is expected to remain relatively stable but may experience further marginal declines due to intense competition and ongoing negotiations with PBMs and large healthcare systems.

• Short-Term (1-2 years): Prices are projected to remain within the current range of $10-$20 per 30-count bottle for the generic product. Significant price increases are unlikely given the mature generic market.
• Medium-Term (3-5 years): Continued pressure from PBMs seeking cost efficiencies could lead to a further 5-10% reduction in ASPs. This is contingent on the continued absence of significant supply disruptions or new clinical data that might differentiate specific generic formulations.
• Long-Term (5+ years): As the market matures further and potentially faces competition from novel therapeutics in depression and anxiety treatment, prices may see continued but slow erosion. The market will likely stabilize around the cost of manufacturing and distribution for generic pharmaceuticals.

Factors influencing projections:

• Generic Market Saturation: The current market is highly saturated with numerous generic suppliers.
• PBM and Payer Negotiations: PBMs will continue to leverage the competitive landscape to secure lower prices for their formularies.
• Manufacturing Costs: Fluctuations in raw material costs and manufacturing efficiencies will impact the floor price for generics.
• Regulatory Environment: Changes in FDA regulations or manufacturing standards could influence supply and cost.
• Emergence of New Therapies: Breakthroughs in treating depression and anxiety could divert market share and impact demand for older generics like escitalopram.

Table 1: Escitalopram Oxalate Price Projection (30-count bottle, Retail Cash Price Estimate)

Timeframe	Projected Price Range (USD)	Key Drivers
Present	$10 - $20	High generic competition, PBM contracts
1-2 Years	$9 - $19	Stable competition, minor PBM negotiation gains
3-5 Years	$8 - $17	Increased payer pressure, mature market
5+ Years	$7 - $15	Market stabilization, potential new therapeutic entry

Note: These are estimated retail cash prices and do not reflect negotiated prices with insurance providers or PBMs, which are typically lower.

What is the Competitive Landscape for Escitalopram?

The competitive landscape is defined by the presence of numerous generic manufacturers offering bioequivalent versions of escitalopram oxalate.

• Market Entry: Generic escitalopram entered the market in late 2012 following the expiration of the primary patent for Cipralex (the brand name in many non-US markets) and Lexapro in the US.
• Competition Intensity: Competition is fierce, with over 20 companies holding ANDAs approved by the FDA. This has driven prices down rapidly.
• Product Differentiation: Differentiation among generic escitalopram products is minimal, primarily focusing on price, availability, and packaging. There is no significant clinical differentiation once bioequivalence is established.
• Therapeutic Alternatives: While escitalopram remains a first-line option, the market also includes other SSRIs (e.g., fluoxetine, sertraline, citalopram) and SNRIs (e.g., venlafaxine, duloxetine), offering physicians and patients alternatives. Newer classes of antidepressants and anxiolytics also compete for market share.

The market dynamics favor large PBMs and payers who can negotiate significant discounts based on volume. Generic manufacturers compete on cost-efficiency and supply chain reliability.

What are the Regulatory Considerations?

Regulatory bodies like the FDA play a critical role in ensuring the safety, efficacy, and quality of both branded and generic drugs.

• ANDA Approval Process: Generic manufacturers must demonstrate bioequivalence to the reference listed drug (Lexapro) through the ANDA process. This ensures comparable pharmacokinetic profiles and therapeutic effects.
• Manufacturing Standards: All manufacturers, including generic ones, must adhere to current Good Manufacturing Practices (cGMP) to ensure product quality and consistency. FDA inspections are a key component of regulatory oversight.
• Labeling Requirements: Generic drug labeling must be essentially the same as the approved labeling for the reference drug, with specific exceptions related to patent status and manufacturer information.
• Post-Market Surveillance: Both branded and generic drugs are subject to post-market surveillance for adverse event reporting and pharmacovigilance.

The regulatory framework supports the availability of safe and effective generic alternatives, thereby driving down healthcare costs.

Key Takeaways

• Lexapro’s primary U.S. patent expired in 2013, leading to extensive generic competition.
• The market for escitalopram oxalate is now dominated by generic manufacturers, with significant price erosion from branded levels.
• Key market drivers include the high prevalence of depression and anxiety disorders and the established clinical efficacy of escitalopram.
• Generic escitalopram prices are projected to remain stable in the short term, with potential for further marginal declines due to payer negotiations and market maturity.
• The competitive landscape is characterized by numerous generic suppliers, minimal product differentiation beyond price, and competition from other antidepressant and anxiolytic classes.
• Regulatory oversight by the FDA ensures the availability of safe and bioequivalent generic escitalopram.

Frequently Asked Questions

1. When did the primary patent for Lexapro expire in the United States? The primary U.S. patent protecting escitalopram, U.S. Patent No. 5,629,321, expired on October 14, 2013.

2. What is the typical price range for a 30-count bottle of generic escitalopram oxalate today? The typical retail cash price range for a 30-count bottle of generic escitalopram oxalate is currently between $10 and $20 USD.

3. Are there any clinical advantages of branded Lexapro over generic escitalopram oxalate? No, once a generic product receives FDA approval, it is considered bioequivalent to the branded product, meaning it has the same active ingredient, dosage form, strength, and route of administration, and performs in the same way in the body.

4. What is the primary reason for the significant price drop in escitalopram oxalate since its launch? The primary reason for the price drop is the expiration of key patents, which allowed numerous generic manufacturers to enter the market, leading to intense price competition.

5. Besides Lexapro, what are other common therapeutic alternatives for major depressive disorder and generalized anxiety disorder? Other common therapeutic alternatives include other SSRIs (e.g., fluoxetine, sertraline, citalopram), SNRIs (e.g., venlafaxine, duloxetine), and newer classes of antidepressants and anxiolytics.

Citations

[1] World Health Organization. (n.d.). Depression. Retrieved from https://www.who.int/news-room/fact-sheets/detail/depression [2] National Institute of Mental Health. (2022). Major Depression. Retrieved from https://www.nimh.nih.gov/health/statistics/major-depression